Table 3. Treatment-related adverse events (N = 155)†.

	Nimotuzumab+Gefitinib (n=78)			Gefitinib (n=75)			P-value
Adverse event	All grades	Grade 1-2	Grade≥3	All grades	Grade 1-2	Grade≥3
	N (%)			N (%)
Acneiform rash	37(47.4%)	35(44.9%)	2 (2.6%)	34(44.2%)	33(42.9%)	1 (1.3%)	0.40
Diarrhea	28 (35.9%)	26 (33.3%)	2 (2.6%)	27 (35.1%)	26 (33.8%)	1 (1.3%)	0.52
Anorexia	27 (34.6%)	25 (32.1%)	2 (2.6%)	21 (27.3%)	18 (23.4%)	3 (3.9%)	0.28
Stomatitis	18 (23.1%)	18 (23.1%)	0 (0%)	20 (26.0%)	20 (26.0%)	0 (0%)	0.40
Dry skin	16 (20.5%)	16 (20.5%)	0 (0%)	16 (20.5%)	16 (20.5%)	0 (0%)	0.40
Pruritus	16 (20.5%)	16 (20.5%)	0 (0%)	16 (20.8%)	16 (20.8%)	0 (0%)	0.56
Paronychia	12 (15.4%)	12 (15.4%)	0 (0%)	13 (16.9%)	13 (16.9%)	0 (0%)	0.48
AST elevation	11(14.1%)	9 (11.5%)	2 (2.6%)	8 (10.4%)	6 (7.8%)	2 (2.6%)	0.32
ALT elevation	10 (12.8%)	8 (10.3%)	2 (2.6%)	8 (10.4%)	5 (6.5%)	3 (3.9%)	0.29
Myalgia	9 (11.6%)	9 (11.6%)	0 (0%)	7 (9.1%)	7 (9.1%)	0 (0%)	0.60
Nausea	8 (10.3%)	8 (10.3%)	0 (0%)	10 (13.0%)	8 (10.4%)	2 (2.6%)	0.39
Vomiting	5 (6.4%)	5 (6.4%)	0 (0%)	4 (5.2%)	4 (5.2%)	0 (0%)	0.50
Thrombocytopenia	5 (6.4%)	5 (6.4%)	1 (1.3%)	3 (3.9%)	3 (3.9%)	0 (0%)	0.56
Neutropenia	4 (5.1%)	4 (5.1%)	0 (0%)	2 (3.9%)	2 (3.9%)	0 (0%)	0.50
Anemia	3 (3.8%)	3 (3.8%)	0 (0%)	4(5.2%)	4(5.2%)	0 (0%)	0.49
Pneumonitis	3 (3.8%)	3 (3.8%)	0 (0%)	3 (3.9%)	2 (2.6%)	1 (1.3%)	0.65

Toxic-effect grades are based on the National Cancer Institute Common Terminology Criteria (version 3.0).